Stifel sees opportunity in Glaukos selloff, adds to Select List

Stifel analyst Thomas Stephan tells investors that the firm’s iDose survey was “solid” and reinforces the firm’s continued long-term bullish stance on the product and on Glaukos (GKOS)’ stock. The recent selloff in shares “appears overdone,” says the analyst, who is adding Glaukos to the Stifel Select List and advises investors use the recent pullback to “opportunistically buy key value drivers of the stock at an attractive valuation.” The firm keeps a Buy rating and $115 price target on Glaukos shares.